Heart Transplantation in Adult patients with Congenital Heart Disease


Pediatric Cardiology Department, Hopital Louis Pradel, Lyon, France (1)
Cardiac Surgery, Hopital Louis Pradel, Lyon, France (2)
Adult Heart Transplant Department, Hopital Louis Pradel, Lyon, France (3)

Since 85% of patients with Congenital Heart Disease (CHD) can currently survive and reach adulthood, Heart Transplantation (HTx) is becoming a novel challenge in adults with CHD (ACHD). The aim of this study was to assess results and outcomes of HTx in ACHD.

Material and methods: Clinical data, demographics and outcomes of patients with underlying diagnosis of CHD transplanted at ≥18 years of age, were retrospectively reviewed.

Results: Among --- adult heart transplantations performed from 1991 to 2011, 20 recipients were ACHD (13 males). Age at transplant was 21.6 ± 4 years (median 19.6). Sixteen of 20 (80%) were performed since 2000 and only 4 (20%) before. CHD included: double inlet single ventricle (10 cases), tricuspid atresia (2), transposition of great arteries (2), unbalanced atrioventricular septal defect (2) and miscellaneous (4 cases: 1 Ebstein anomaly, 1 HLHS, 1 ALCAPA, 1 double outlet right ventricle). Seventeen had at least one previous cardiac surgery (85%), i.e: Fontan procedure in 5 (25%), palliative procedures in 10 (50%) and Mustard operation in 2 (10%). Three cases had no previous cardiac surgery (15%), i.e: 1 Ebstein, and 2 unbalanced AVSD.

Two early deaths occurred at day-1 and day-23 post-transplant, due to pulmonary hypertension and graft RV failure. One late death occurred at 9.6 year FU post-transplant, and one patient underwent re-HTx at 6-year FU, due to graft coronary artery disease. Follow-up post-transplant was 6.4 ± 5.3 years (1 to 20.9, median 5.3). Survival rates were 90% at 1 and 5-years post-transplant and 72% at 10 and 15 years. All survivors (17 cases= 85%) are doing well in NYHA class I. Overall < 1 year mortality. Fontan procedure, gender, pre-transplant status did not impact significantly on survival.

Conclusion: The results of this small sample size study shows that HTx is an acceptable option for ACHD patients with end-stage failure of myocardial function and no other therapeutic alternative.